Where can I read JNJ's latest 10-K?

JNJ's latest annual report, a 10-K, was filed on Feb 11, 2026 for the fiscal year ended Dec 28, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.

When did JNJ last file an 8-K?

On Aug 4, 2026: directors or officers; compensation. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 15, 2026.

Are JNJ insiders buying or selling?

Over the last 13 months insiders sold $150.7M in 16 sales and bought nothing on the open market; 165 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Schmid Timothy (EVP, WW Chair, MedTech) sold 33,597 shares on Sep 2, 2026 for $9.2M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.

How many SEC filings has JNJ made?

3,354 filings are on EDGAR under the registrant records that have been Johnson & Johnson, going back to 1994; 1,978 of them are insider ownership forms (Forms 3, 4, 5 and 144).

Share this page

JNJ

$256.03-1.02%

as of close, Oct 2, 2026

☾ AH $256.03 -1.02%

Johnson & JohnsonStock · HealthcareDow Jones 2.9%S&P 500 0.9%Russell 1000 0.9%US Stock Market 0.8%Russell 3000 0.8%MSCI ACWI 0.6%MSCI World 0.6%S&P 500 Equal Weight 0.2%

PeersMRNALLYUNHMRKTMOAMGN

JNJ SEC filings (2026)

CIK 200406 · Pharmaceutical Preparations (SIC 2834) · incorporated in NJ · fiscal year ends in January

3,354 filings on EDGAR since 1994 · 43 annual, 107 quarterly, 324 current · financial statements · earnings

Latest 10-K

Feb 11, 2026

fiscal year to Dec 28, 2025

Latest 10-Q

Jul 23, 2026

quarter to Jun 28, 2026

Latest 8-K

Aug 4, 2026

Directors or officers; compensation

Last earnings release

Jul 15, 2026

$2.90 vs $2.84 · ▼ 2.7%

Filings on file

3,354

since 1994, 1,978 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $150.7M in 16 sales and bought nothing on the open market; 165 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Sep 2, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechSold · $9.2M · 33,597 sh	Sold	33,597	$274.74	$9.2M	25,447	Form 4
Aug 17, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineSold · $4.0M · 15,000 sh	Sold	15,000	$263.36	$4.0M	194,451.001	Form 4
Aug 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorSold · $32.2M · 123,291 sh	Sold	123,291	$261.00–$262.00	$32.2M	275,967	Form 4
Aug 6, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerSold · $4.1M · 15,918 sh	Sold	15,918	$255.93–$257.76	$4.1M	16,994	Form 4
Aug 5, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorSold · $12.5M · 48,480 sh	Sold	48,480	$258.06–$258.74	$12.5M	275,967	Form 4
Jul 20, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsSold · $5.8M · 23,054 sh	Sold	23,054	$251.27	$5.8M	23,003	Form 4
Jun 11, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerSold · $2.4M · 10,000 sh	Sold	10,000	$241.15	$2.4M	114,287.874	Form 4
Feb 27, 2026Form 4	Decker Robert JVP Corporate ControllerSold · $1.0M · 4,075 sh	Sold	4,075	$247.87	$1.0M	23,682	Form 4
Feb 20, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechSold · $325K · 1,322 sh	Sold	1,322	$245.66	$325K	25,447	Form 4
Feb 18, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechSold · $5.5M · 22,623 sh	Sold	22,623	$244.20–$244.53	$5.5M	26,769	Form 4
Feb 17, 2026Form 4	Wolk Joseph JExec VP, CFOSold · $21.8M · 89,654 sh	Sold	89,654	$242.68–$242.99	$21.8M	14,000	Form 4
Feb 17, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DSold · $13.1M · 53,931 sh	Sold	53,931	$243.00	$13.1M	10,658	Form 4
Feb 17, 2026Form 4	Swanson James D.EVP, CIOSold · $5.0M · 20,521 sh	Sold	20,521	$242.70	$5.0M	25,698.131	Form 4
Feb 17, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsSold · $1.5M · 6,197 sh	Sold	6,197	$243.39	$1.5M	23,003	Form 4
Feb 13, 2026Form 4	Swanson James D.EVP, CIOSold · $10.1M · 41,559 sh	Sold	41,559	$243.71–$243.76	$10.1M	25,020.131	Form 4
Jan 26, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorSold · $22.1M · 100,000 sh	Sold	100,000	$220.99–$221.48	$22.1M	30,852	Form 4

Awards, exercises, withholding and plan purchases · 165 transactions

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Sep 8, 2026Form 4	HEWSON MARILLYN ADirectorAward · Deferred Share Units · $50K · 180.956 sh	Award· Deferred Share Units	180.956	$276.31	$50K	16,049.417	Form 4
Sep 8, 2026Form 4	Woods Eugene A.DirectorAward · Deferred Share Units · $37K · 135.717 sh	Award· Deferred Share Units	135.717	$276.31	$37K	6,578.771	Form 4
Sep 8, 2026Form 4	Pinto Daniel EDirectorAward · Deferred Share Units · $31K · 113.098 sh	Award· Deferred Share Units	113.098	$276.31	$31K	2,445.177	Form 4
Sep 2, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · $4.9M · 33,597 sh	Exercise or conversion	33,597	$131.94–$151.41	$4.9M	47,974	Form 4
Sep 2, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · Employee Stock Options (Ri… · $0 · 33,597 sh	Exercise or conversion· Employee Stock Options (Ri…	33,597	$0.00	$0	0	Form 4
Aug 17, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · $1.7M · 15,000 sh	Exercise or conversion	15,000	$115.67	$1.7M	209,451.001	Form 4
Aug 17, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · Employee Stock Options (Ri… · $0 · 15,000 sh	Exercise or conversion· Employee Stock Options (Ri…	15,000	$0.00	$0	28,712	Form 4
Aug 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · $14.3M · 123,291 sh	Exercise or conversion	123,291	$115.67	$14.3M	399,258	Form 4
Aug 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · Employee Stock Options (Ri… · $0 · 123,291 sh	Exercise or conversion· Employee Stock Options (Ri…	123,291	$0.00	$0	0	Form 4
Aug 6, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · $1.2M · 9,344 sh	Exercise or conversion	9,344	$131.94	$1.2M	32,912	Form 4
Aug 6, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · Employee Stock Options (Ri… · $0 · 9,344 sh	Exercise or conversion· Employee Stock Options (Ri…	9,344	$0.00	$0	0	Form 4
Jul 20, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · $3.0M · 23,054 sh	Exercise or conversion	23,054	$129.51–$131.94	$3.0M	46,057	Form 4
Jul 20, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · Employee Stock Options (Ri… · $0 · 23,054 sh	Exercise or conversion· Employee Stock Options (Ri…	23,054	$0.00	$0	0	Form 4
Jun 11, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · $1.2M · 10,000 sh	Exercise or conversion	10,000	$115.67	$1.2M	124,287.874	Form 4
Jun 11, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · Employee Stock Options (Ri… · $0 · 10,000 sh	Exercise or conversion· Employee Stock Options (Ri…	10,000	$0.00	$0	32,965	Form 4
Jun 9, 2026Form 4	HEWSON MARILLYN ADirectorAward · Deferred Share Units · $50K · 214.786 sh	Award· Deferred Share Units	214.786	$232.79	$50K	15,791.877	Form 4
Jun 9, 2026Form 4	Woods Eugene A.DirectorAward · Deferred Share Units · $37K · 161.089 sh	Award· Deferred Share Units	161.089	$232.79	$37K	6,411.959	Form 4
Jun 9, 2026Form 4	Pinto Daniel EDirectorAward · Deferred Share Units · $31K · 134.241 sh	Award· Deferred Share Units	134.241	$232.79	$31K	2,320.824	Form 4
May 1, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DTax withholding · $2.5M · 11,002 sh	Tax withholding	11,002	$229.85	$2.5M	24,911	Form 4
May 1, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DExercise or conversion · $0 · 25,255 sh	Exercise or conversion	25,255	$0.00	$0	35,913	Form 4
May 1, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DExercise or conversion · Restricted Share Units · $0 · 25,255 sh	Exercise or conversion· Restricted Share Units	25,255	$0.00	$0	0	Form 4
Apr 23, 2026Form 4	Pinto Daniel EDirectorAward · Deferred Share Units · $0 · 1,712 sh	Award· Deferred Share Units	1,712	$0.00	$0	2,174.069	Form 4
Apr 23, 2026Form 4	MORIKIS JOHN GDirectorAward · Deferred Share Units · $0 · 1,540 sh	Award· Deferred Share Units	1,540	$0.00	$0	1,540	Form 4
Apr 23, 2026Form 4	Beckerle Mary CDirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	16,797.739	Form 4
Apr 23, 2026Form 4	Doudna Jennifer ADirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	10,899.171	Form 4
Apr 23, 2026Form 4	HEWSON MARILLYN ADirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	15,487.939	Form 4
Apr 23, 2026Form 4	Johnson Paula ADirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	5,359.397	Form 4
Apr 23, 2026Form 4	Joly HubertDirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	9,183.605	Form 4
Apr 23, 2026Form 4	McClellan Mark B.DirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	21,278.593	Form 4
Apr 23, 2026Form 4	WEINBERGER MARK ADirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	12,010.408	Form 4
Apr 23, 2026Form 4	West NadjaDirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	7,730.049	Form 4
Apr 23, 2026Form 4	Woods Eugene A.DirectorAward · Deferred Share Units · $0 · 975 sh	Award· Deferred Share Units	975	$0.00	$0	6,215.094	Form 4
Mar 10, 2026Form 4	HEWSON MARILLYN ADirectorAward · Deferred Share Units · $50K · 206.492 sh	Award· Deferred Share Units	206.492	$242.14	$50K	14,512.94	Form 4
Mar 10, 2026Form 4	Woods Eugene A.DirectorAward · Deferred Share Units · $37K · 154.869 sh	Award· Deferred Share Units	154.869	$242.14	$37K	5,240.094	Form 4
Mar 10, 2026Form 4	Pinto Daniel EDirectorAward · Deferred Share Units · $31K · 129.058 sh	Award· Deferred Share Units	129.058	$242.14	$31K	462.069	Form 4
Feb 27, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · $471K · 4,075 sh	Exercise or conversion	4,075	$115.67	$471K	27,757	Form 4
Feb 27, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · Employee Stock Options (Ri… · $0 · 4,075 sh	Exercise or conversion· Employee Stock Options (Ri…	4,075	$0.00	$0	0	Form 4
Feb 18, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · $2.7M · 22,623 sh	Exercise or conversion	22,623	$115.67–$129.51	$2.7M	35,767	Form 4
Feb 18, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · Employee Stock Options (Ri… · $0 · 22,623 sh	Exercise or conversion· Employee Stock Options (Ri…	22,623	$0.00	$0	0	Form 4
Feb 17, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · $8.2M · 64,693 sh	Exercise or conversion	64,693	$115.67–$131.94	$8.2M	72,347	Form 4
Feb 17, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DExercise or conversion · $8.1M · 51,648 sh	Exercise or conversion	51,648	$156.15–$157.92	$8.1M	42,868	Form 4
Feb 17, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · $3.4M · 20,521 sh	Exercise or conversion	20,521	$164.62	$3.4M	46,219.131	Form 4
Feb 17, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · Employee Stock Options (Ri… · $0 · 64,693 sh	Exercise or conversion· Employee Stock Options (Ri…	64,693	$0.00	$0	33,000	Form 4
Feb 17, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DExercise or conversion · Employee Stock Options (Ri… · $0 · 51,648 sh	Exercise or conversion· Employee Stock Options (Ri…	51,648	$0.00	$0	59,854	Form 4
Feb 17, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · Employee Stock Options (Ri… · $0 · 20,521 sh	Exercise or conversion· Employee Stock Options (Ri…	20,521	$0.00	$0	0	Form 4
Feb 15, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorTax withholding · $867K · 3,562 sh	Tax withholding	3,562	$243.45	$867K	324,447	Form 4
Feb 15, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineTax withholding · $429K · 1,761 sh	Tax withholding	1,761	$243.45	$429K	194,451.001	Form 4
Feb 15, 2026Form 4	Wolk Joseph JExec VP, CFOTax withholding · $408K · 1,675 sh	Tax withholding	1,675	$243.45	$408K	38,961	Form 4
Feb 15, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerTax withholding · $252K · 1,036 sh	Tax withholding	1,036	$243.45	$252K	23,568	Form 4
Feb 15, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DTax withholding · $222K · 913 sh	Tax withholding	913	$243.45	$222K	12,941	Form 4
Feb 15, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerTax withholding · $155K · 635 sh	Tax withholding	635	$243.45	$155K	114,287.874	Form 4
Feb 15, 2026Form 4	Swanson James D.EVP, CIOTax withholding · $127K · 523 sh	Tax withholding	523	$243.45	$127K	25,698.131	Form 4
Feb 15, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsTax withholding · $127K · 522 sh	Tax withholding	522	$243.45	$127K	29,200	Form 4
Feb 15, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechTax withholding · $113K · 463 sh	Tax withholding	463	$243.45	$113K	26,769	Form 4
Feb 15, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerTax withholding · $103K · 423 sh	Tax withholding	423	$243.45	$103K	19,830	Form 4
Feb 15, 2026Form 4	Decker Robert JVP Corporate ControllerTax withholding · $46K · 189 sh	Tax withholding	189	$243.45	$46K	23,682	Form 4
Feb 15, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorAward · Employee Stock Options (Ri… · $0 · 131,734 sh	Award· Employee Stock Options (Ri…	131,734	$0.00	$0	131,734	Form 4
Feb 15, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineAward · Employee Stock Options (Ri… · $0 · 54,869 sh	Award· Employee Stock Options (Ri…	54,869	$0.00	$0	54,869	Form 4
Feb 15, 2026Form 4	Wolk Joseph JExec VP, CFOAward · Employee Stock Options (Ri… · $0 · 53,793 sh	Award· Employee Stock Options (Ri…	53,793	$0.00	$0	53,793	Form 4
Feb 15, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DAward · Employee Stock Options (Ri… · $0 · 49,382 sh	Award· Employee Stock Options (Ri…	49,382	$0.00	$0	49,382	Form 4
Feb 15, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechAward · Employee Stock Options (Ri… · $0 · 35,489 sh	Award· Employee Stock Options (Ri…	35,489	$0.00	$0	35,489	Form 4
Feb 15, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerAward · Employee Stock Options (Ri… · $0 · 27,076 sh	Award· Employee Stock Options (Ri…	27,076	$0.00	$0	27,076	Form 4
Feb 15, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerAward · Employee Stock Options (Ri… · $0 · 20,322 sh	Award· Employee Stock Options (Ri…	20,322	$0.00	$0	20,322	Form 4
Feb 15, 2026Form 4	Swanson James D.EVP, CIOAward · Employee Stock Options (Ri… · $0 · 19,449 sh	Award· Employee Stock Options (Ri…	19,449	$0.00	$0	19,449	Form 4
Feb 15, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerAward · Employee Stock Options (Ri… · $0 · 16,945 sh	Award· Employee Stock Options (Ri…	16,945	$0.00	$0	16,945	Form 4
Feb 15, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsAward · Employee Stock Options (Ri… · $0 · 14,405 sh	Award· Employee Stock Options (Ri…	14,405	$0.00	$0	14,405	Form 4
Feb 15, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorAward · Restricted Share Units · $0 · 9,459 sh	Award· Restricted Share Units	9,459	$0.00	$0	9,459	Form 4
Feb 15, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · $0 · 8,187 sh	Exercise or conversion	8,187	$0.00	$0	326,407	Form 4
Feb 15, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · Restricted Share Units · $0 · 8,187 sh	Exercise or conversion· Restricted Share Units	8,187	$0.00	$0	9,008	Form 4
Feb 15, 2026Form 4	Decker Robert JVP Corporate ControllerAward · Employee Stock Options (Ri… · $0 · 4,871 sh	Award· Employee Stock Options (Ri…	4,871	$0.00	$0	4,871	Form 4
Feb 15, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineAward · Restricted Share Units · $0 · 3,940 sh	Award· Restricted Share Units	3,940	$0.00	$0	3,940	Form 4
Feb 15, 2026Form 4	Wolk Joseph JExec VP, CFOAward · Restricted Share Units · $0 · 3,863 sh	Award· Restricted Share Units	3,863	$0.00	$0	3,863	Form 4
Feb 15, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · $0 · 3,849 sh	Exercise or conversion	3,849	$0.00	$0	39,778	Form 4
Feb 15, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · Restricted Share Units · $0 · 3,849 sh	Exercise or conversion· Restricted Share Units	3,849	$0.00	$0	3,754	Form 4
Feb 15, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DAward · Restricted Share Units · $0 · 3,546 sh	Award· Restricted Share Units	3,546	$0.00	$0	3,546	Form 4
Feb 15, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · $0 · 3,441 sh	Exercise or conversion	3,441	$0.00	$0	195,396.001	Form 4
Feb 15, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · Restricted Share Units · $0 · 3,441 sh	Exercise or conversion· Restricted Share Units	3,441	$0.00	$0	3,692	Form 4
Feb 15, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DExercise or conversion · $0 · 3,196 sh	Exercise or conversion	3,196	$0.00	$0	13,469	Form 4
Feb 15, 2026Form 4	REED JOHN CEVP, Innovative Medicine, R&DExercise or conversion · Restricted Share Units · $0 · 3,196 sh	Exercise or conversion· Restricted Share Units	3,196	$0.00	$0	3,692	Form 4
Feb 15, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechAward · Restricted Share Units · $0 · 2,548 sh	Award· Restricted Share Units	2,548	$0.00	$0	2,548	Form 4
Feb 15, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · $0 · 2,054 sh	Exercise or conversion	2,054	$0.00	$0	27,217	Form 4
Feb 15, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · Restricted Share Units · $0 · 2,054 sh	Exercise or conversion· Restricted Share Units	2,054	$0.00	$0	2,051	Form 4
Feb 15, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · $0 · 2,024 sh	Exercise or conversion	2,024	$0.00	$0	24,112	Form 4
Feb 15, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · Restricted Share Units · $0 · 2,024 sh	Exercise or conversion· Restricted Share Units	2,024	$0.00	$0	2,126	Form 4
Feb 15, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerAward · Restricted Share Units · $0 · 1,944 sh	Award· Restricted Share Units	1,944	$0.00	$0	1,944	Form 4
Feb 15, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerAward · Restricted Share Units · $0 · 1,459 sh	Award· Restricted Share Units	1,459	$0.00	$0	1,459	Form 4
Feb 15, 2026Form 4	Swanson James D.EVP, CIOAward · Restricted Share Units · $0 · 1,397 sh	Award· Restricted Share Units	1,397	$0.00	$0	1,397	Form 4
Feb 15, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · $0 · 1,241 sh	Exercise or conversion	1,241	$0.00	$0	114,612.874	Form 4
Feb 15, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · Restricted Share Units · $0 · 1,241 sh	Exercise or conversion· Restricted Share Units	1,241	$0.00	$0	1,268	Form 4
Feb 15, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerAward · Restricted Share Units · $0 · 1,217 sh	Award· Restricted Share Units	1,217	$0.00	$0	1,217	Form 4
Feb 15, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · $0 · 1,201 sh	Exercise or conversion	1,201	$0.00	$0	26,007.131	Form 4
Feb 15, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · Restricted Share Units · $0 · 1,201 sh	Exercise or conversion· Restricted Share Units	1,201	$0.00	$0	1,418	Form 4
Feb 15, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsAward · Restricted Share Units · $0 · 1,034 sh	Award· Restricted Share Units	1,034	$0.00	$0	1,034	Form 4
Feb 15, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · $0 · 1,018 sh	Exercise or conversion	1,018	$0.00	$0	29,470	Form 4
Feb 15, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · Restricted Share Units · $0 · 1,018 sh	Exercise or conversion· Restricted Share Units	1,018	$0.00	$0	1,050	Form 4
Feb 15, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerExercise or conversion · $0 · 994 sh	Exercise or conversion	994	$0.00	$0	20,081	Form 4
Feb 15, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerExercise or conversion · Restricted Share Units · $0 · 994 sh	Exercise or conversion· Restricted Share Units	994	$0.00	$0	1,150	Form 4
Feb 15, 2026Form 4	Decker Robert JVP Corporate ControllerAward · Restricted Share Units · $0 · 700 sh	Award· Restricted Share Units	700	$0.00	$0	700	Form 4
Feb 15, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · $0 · 683 sh	Exercise or conversion	683	$0.00	$0	23,777	Form 4
Feb 15, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · Restricted Share Units · $0 · 683 sh	Exercise or conversion· Restricted Share Units	683	$0.00	$0	687	Form 4
Feb 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorTax withholding · $8.0M · 32,668 sh	Tax withholding	32,668	$244.55	$8.0M	319,822	Form 4
Feb 13, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · $6.8M · 51,418 sh	Exercise or conversion	51,418	$0.00–$165.89	$6.8M	47,211.131	Form 4
Feb 13, 2026Form 4	Wolk Joseph JExec VP, CFOTax withholding · $4.0M · 16,455 sh	Tax withholding	16,455	$244.55	$4.0M	36,787	Form 4
Feb 13, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineTax withholding · $3.4M · 13,956 sh	Tax withholding	13,956	$244.55	$3.4M	192,771.001	Form 4
Feb 13, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerTax withholding · $1.8M · 7,325 sh	Tax withholding	7,325	$244.55	$1.8M	22,580	Form 4
Feb 13, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerTax withholding · $1.6M · 6,631 sh	Tax withholding	6,631	$244.55	$1.6M	113,681.874	Form 4
Feb 13, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsTax withholding · $952K · 3,892 sh	Tax withholding	3,892	$244.55	$952K	28,704	Form 4
Feb 13, 2026Form 4	Swanson James D.EVP, CIOTax withholding · $902K · 3,690 sh	Tax withholding	3,690	$244.55	$902K	25,020.131	Form 4
Feb 13, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechTax withholding · $446K · 1,824 sh	Tax withholding	1,824	$244.55	$446K	25,178	Form 4
Feb 13, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerTax withholding · $284K · 1,162 sh	Tax withholding	1,162	$244.55	$284K	19,259	Form 4
Feb 13, 2026Form 4	Decker Robert JVP Corporate ControllerTax withholding · $212K · 866 sh	Tax withholding	866	$244.55	$212K	23,188	Form 4
Feb 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · $0 · 76,523 sh	Exercise or conversion	76,523	$0.00	$0	351,501	Form 4
Feb 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · Performance Share Units · $0 · 73,054 sh	Exercise or conversion· Performance Share Units	73,054	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · Employee Stock Options (Ri… · $0 · 41,559 sh	Exercise or conversion· Employee Stock Options (Ri…	41,559	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · $0 · 39,242 sh	Exercise or conversion	39,242	$0.00	$0	37,294	Form 4
Feb 13, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · Performance Share Units · $0 · 37,463 sh	Exercise or conversion· Performance Share Units	37,463	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · $0 · 28,714 sh	Exercise or conversion	28,714	$0.00	$0	206,318.001	Form 4
Feb 13, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · Performance Share Units · $0 · 27,412 sh	Exercise or conversion· Performance Share Units	27,412	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · $0 · 14,357 sh	Exercise or conversion	14,357	$0.00	$0	29,591	Form 4
Feb 13, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · $0 · 14,357 sh	Exercise or conversion	14,357	$0.00	$0	120,095.874	Form 4
Feb 13, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · Performance Share Units · $0 · 13,706 sh	Exercise or conversion· Performance Share Units	13,706	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · Performance Share Units · $0 · 13,706 sh	Exercise or conversion· Performance Share Units	13,706	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · Performance Share Units · $0 · 9,412 sh	Exercise or conversion· Performance Share Units	9,412	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · $0 · 9,002 sh	Exercise or conversion	9,002	$0.00	$0	32,452	Form 4
Feb 13, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · Performance Share Units · $0 · 8,594 sh	Exercise or conversion· Performance Share Units	8,594	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · $0 · 4,877 sh	Exercise or conversion	4,877	$0.00	$0	26,994	Form 4
Feb 13, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · Performance Share Units · $0 · 4,378 sh	Exercise or conversion· Performance Share Units	4,378	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerExercise or conversion · $0 · 4,012 sh	Exercise or conversion	4,012	$0.00	$0	20,286	Form 4
Feb 13, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerExercise or conversion · Performance Share Units · $0 · 3,602 sh	Exercise or conversion· Performance Share Units	3,602	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorExercise or conversion · Restricted Share Units · $0 · 3,469 sh	Exercise or conversion· Restricted Share Units	3,469	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · $0 · 3,053 sh	Exercise or conversion	3,053	$0.00	$0	23,950	Form 4
Feb 13, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · Performance Share Units · $0 · 2,741 sh	Exercise or conversion· Performance Share Units	2,741	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Wolk Joseph JExec VP, CFOExercise or conversion · Restricted Share Units · $0 · 1,779 sh	Exercise or conversion· Restricted Share Units	1,779	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion · Restricted Share Units · $0 · 1,302 sh	Exercise or conversion· Restricted Share Units	1,302	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion · Restricted Share Units · $0 · 651 sh	Exercise or conversion· Restricted Share Units	651	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerExercise or conversion · Restricted Share Units · $0 · 651 sh	Exercise or conversion· Restricted Share Units	651	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechExercise or conversion · Restricted Share Units · $0 · 499 sh	Exercise or conversion· Restricted Share Units	499	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Swanson James D.EVP, CIOExercise or conversion · Restricted Share Units · $0 · 447 sh	Exercise or conversion· Restricted Share Units	447	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerExercise or conversion · Restricted Share Units · $0 · 410 sh	Exercise or conversion· Restricted Share Units	410	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsExercise or conversion · Restricted Share Units · $0 · 408 sh	Exercise or conversion· Restricted Share Units	408	$0.00	$0	0	Form 4
Feb 13, 2026Form 4	Decker Robert JVP Corporate ControllerExercise or conversion · Restricted Share Units · $0 · 312 sh	Exercise or conversion· Restricted Share Units	312	$0.00	$0	0	Form 4
Feb 9, 2026Form 4	Duato JoaquinCEO and Chairman of the Board · DirectorAward · Performance Share Units · $0 · 73,054 sh	Award· Performance Share Units	73,054	$0.00	$0	73,054	Form 4
Feb 9, 2026Form 4	Wolk Joseph JExec VP, CFOAward · Performance Share Units · $0 · 37,463 sh	Award· Performance Share Units	37,463	$0.00	$0	37,463	Form 4
Feb 9, 2026Form 4	Taubert Jennifer LEVP, WWC. Innovative MedicineAward · Performance Share Units · $0 · 27,412 sh	Award· Performance Share Units	27,412	$0.00	$0	27,412	Form 4
Feb 9, 2026Form 4	Wengel Kathryn EEVP, Chief TO and Risk OfficerAward · Performance Share Units · $0 · 13,706 sh	Award· Performance Share Units	13,706	$0.00	$0	13,706	Form 4
Feb 9, 2026Form 4	Forminard ElizabethEVP, Chief Legal OfficerAward · Performance Share Units · $0 · 13,706 sh	Award· Performance Share Units	13,706	$0.00	$0	13,706	Form 4
Feb 9, 2026Form 4	Swanson James D.EVP, CIOAward · Performance Share Units · $0 · 9,412 sh	Award· Performance Share Units	9,412	$0.00	$0	9,412	Form 4
Feb 9, 2026Form 4	Broadhurst VanessaEVP, Global Corp AffairsAward · Performance Share Units · $0 · 8,594 sh	Award· Performance Share Units	8,594	$0.00	$0	8,594	Form 4
Feb 9, 2026Form 4	Schmid TimothyEVP, WW Chair, MedTechAward · Performance Share Units · $0 · 4,378 sh	Award· Performance Share Units	4,378	$0.00	$0	4,378	Form 4
Feb 9, 2026Form 4	Mulholland KristenEVP, Chief HR OfficerAward · Performance Share Units · $0 · 3,602 sh	Award· Performance Share Units	3,602	$0.00	$0	3,602	Form 4

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).

2026 · 13 filings

Filed	Form	What it is	Period
Aug 4, 20268-K	8-K	Directors or officers; compensation	Aug 4, 2026
Jul 29, 20268-K	8-K	Regulation FD disclosure	Jul 29, 2026
Jul 28, 20268-K	8-K	Regulation FD disclosure	Jul 27, 2026
Jul 23, 202610-Q	10-Q	Quarterly report, Q2 2026 — revenue $25.31B (+7% y/y), net income $5.53B, EPS $2.27	Jun 28, 2026
Jul 15, 20268-K	8-K	Earnings release — EPS $2.90 vs $2.84 est. (+2.1%); revenue $25.31B (+7% y/y) 2.7%	Jul 15, 2026
Apr 28, 20268-K	8-K	Shareholder vote results	Apr 23, 2026
Apr 22, 202610-Q	10-Q	Quarterly report, Q1 2026 — revenue $24.06B (+10% y/y), net income $5.24B, EPS $2.14	Mar 29, 2026
Apr 14, 20268-K	8-K	Earnings release — EPS $2.70 vs $2.67 est. (+1.1%); revenue $24.06B (+10% y/y) 0.9%	Apr 14, 2026
Mar 11, 2026ARS	ARS	Annual report to shareholders	Dec 28, 2025
Mar 11, 2026DEFA14A	DEFA14A	Additional proxy materials	—
Mar 11, 2026DEF 14A	DEF 14A	Proxy statement	Mar 11, 2026
Feb 11, 202610-K	10-K	Annual report, FY2025 — revenue $94.19B (+6% y/y), net income $26.80B, EPS $11.03	Dec 28, 2025
Jan 21, 20268-K	8-K	Earnings release — EPS $2.46 vs $2.43 est. (+1.2%); revenue $24.56B (+9% y/y) 0.1%	Jan 21, 2026

2025 · 24 filings

Filed	Form	What it is	Period
Oct 22, 202510-Q	10-Q	Quarterly report, Q3 2025 — revenue $23.99B (+7% y/y), net income $5.15B, EPS $2.12	Sep 28, 2025
Oct 14, 20258-K	8-K	Earnings release — EPS $2.80 vs $2.77 est. (+1.1%); revenue $23.99B (+7% y/y) 0.0%	Oct 14, 2025
Sep 9, 20258-K	8-K	Directors or officers; compensation	Sep 8, 2025
Jul 24, 202510-Q	10-Q	Quarterly report, Q2 2025 — revenue $23.74B (+6% y/y), net income $5.54B, EPS $2.29	Jun 29, 2025
Jul 16, 20258-K	8-K	Results of operations	Jul 16, 2025
Jun 10, 20258-K	8-K	Directors or officers; compensation	Jun 10, 2025
Apr 30, 20258-K	8-K	Directors or officers; compensation; Shareholder vote results	Apr 24, 2025
Apr 23, 202510-Q	10-Q	Quarterly report, Q1 2025 — revenue $21.89B (+2% y/y), net income $11.00B, EPS $4.54	Mar 30, 2025
Apr 23, 2025PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 15, 20258-K	8-K	Results of operations; Other events	Apr 15, 2025
Apr 3, 20258-K	8-K	Regulation FD disclosure	Mar 31, 2025
Mar 20, 2025PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 12, 2025DEFA14A	DEFA14A	Additional proxy materials	—
Mar 12, 2025ARS	ARS	Annual report to shareholders	Dec 29, 2024
Mar 12, 2025DEF 14A	DEF 14A	Proxy statement	Mar 12, 2025
Mar 7, 2025DFAN14A	DFAN14A	Proxy statements	—
Feb 26, 20258-K	8-K	Other events	Feb 26, 2025
Feb 25, 2025DFAN14A	DFAN14A	Proxy statements	—
Feb 20, 20258-K	8-K	Other events	Feb 20, 2025
Feb 13, 202510-K	10-K	Annual report, FY2024 — revenue $88.82B (+4% y/y), net income $14.07B, EPS $5.79	Dec 29, 2024
Jan 22, 2025DFAN14A	DFAN14A	Proxy statements	—
Jan 22, 20258-K/A	8-K/A	Financial statements and exhibits	Jan 22, 2025
Jan 22, 20258-K	8-K	Results of operations	Jan 22, 2025
Jan 13, 2025DFAN14A	DFAN14A	Proxy statements	—

2024 · 27 filings

Filed	Form	What it is	Period
Oct 23, 202410-Q	10-Q	Quarterly report, Q3 2024 — revenue $22.47B (+5% y/y), net income $2.69B, EPS $1.11	Sep 29, 2024
Oct 15, 20248-K	8-K	Results of operations	Oct 15, 2024
Sep 20, 20248-K	8-K	Regulation FD disclosure	Sep 20, 2024
Sep 10, 20248-K	8-K	Directors or officers; compensation	Sep 10, 2024
Aug 26, 20248-K	8-K	Directors or officers; compensation	Aug 26, 2024
Jul 25, 202410-Q	10-Q	Quarterly report, Q2 2024 — revenue $22.45B (+4% y/y), net income $4.69B, EPS $1.93	Jun 30, 2024
Jul 17, 20248-K	8-K	Results of operations	Jul 17, 2024
May 20, 20248-K	8-K	Other events	May 20, 2024
May 17, 20248-K	8-K	Other events	May 17, 2024
May 1, 202410-Q	10-Q	Quarterly report, Q1 2024 — revenue $21.38B (+2% y/y), net income $3.25B, EPS $1.34	Mar 31, 2024
May 1, 20248-K	8-K	Results of operations; Regulation FD disclosure	May 1, 2024
Apr 29, 20248-K	8-K	Charter, bylaws or fiscal-year change; Shareholder vote results	Apr 25, 2024
Apr 16, 20248-K/A	8-K/A	Financial statements and exhibits	Apr 16, 2024
Apr 16, 20248-K	8-K	Results of operations; Other events	Apr 16, 2024
Apr 5, 2024DFAN14A	DFAN14A	Proxy statements	—
Mar 27, 2024PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 13, 2024ARS	ARS	Annual report to shareholders	Dec 31, 2023
Mar 13, 2024DEFA14A	DEFA14A	Additional proxy materials	—
Mar 13, 2024DEFA14A	DEFA14A	Additional proxy materials	—
Mar 13, 2024DEF 14A	DEF 14A	Proxy statement	Apr 25, 2024
Feb 16, 202410-K	10-K	Annual report, FY2023 — revenue $85.16B (+6% y/y), net income $35.15B, EPS $13.72	Dec 31, 2023
Feb 15, 2024DFAN14A	DFAN14A	Proxy statements	—
Jan 29, 2024DFAN14A	DFAN14A	Proxy statements	—
Jan 23, 20248-K	8-K	Results of operations	Jan 23, 2024
Jan 9, 2024DFAN14A	DFAN14A	Proxy statements	—
Jan 8, 2024DFAN14A	DFAN14A	Proxy statements	—
Jan 8, 2024DEFA14A	DEFA14A	Additional proxy materials	—

2023 · 33 filings — 18 × 8-K, 5 × DEFA14A, 3 × 10-Q and 5 other forms

Filed	Form	What it is	Period
Oct 27, 202310-Q	10-Q	Quarterly report, Q3 2023 — revenue $21.35B (+7% y/y), net income $26.03B, EPS $10.21	Oct 1, 2023
Jul 31, 202310-Q	10-Q	Quarterly report, Q2 2023 — revenue $21.52B (+6% y/y), net income $5.14B, EPS $1.96	Jul 2, 2023
Apr 28, 202310-Q	10-Q	Quarterly report, Q1 2023 — revenue $20.89B (+5% y/y), net income −$68.0M, EPS −$0.03	Apr 2, 2023
Apr 19, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Apr 13, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Apr 12, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 10, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 28, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Mar 22, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 16, 2023ARS	ARS	Annual report to shareholders	Jan 1, 2023
Mar 15, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Mar 15, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Mar 15, 2023DEF 14A	DEF 14A	Proxy statement	—
Feb 16, 202310-K	10-K	Annual report, FY2022 — revenue $79.99B (+2% y/y), net income $17.94B, EPS $6.73	Jan 1, 2023

19 current reports (8-K) not listed; the year is on EDGAR.

2022 · 24 filings — 12 × 8-K, 5 × PX14A6G, 3 × 10-Q and 3 other forms

Filed	Form	What it is	Period
Oct 27, 202210-Q	10-Q	Quarterly report, Q3 2022 — revenue $20.00B (−14% y/y), net income $4.46B, EPS $1.68	Oct 2, 2022
Jul 29, 202210-Q	10-Q	Quarterly report, Q2 2022 — revenue $20.21B (−13% y/y), net income $4.81B, EPS $1.80	Jul 3, 2022
Apr 29, 202210-Q	10-Q	Quarterly report, Q1 2022 — revenue $19.84B (−11% y/y), net income $5.15B, EPS $1.93	Apr 3, 2022
Apr 1, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 31, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 29, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 22, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 17, 2022DEFA14A	DEFA14A	Additional proxy materials	—
Mar 17, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 16, 2022DEFA14A	DEFA14A	Additional proxy materials	—
Mar 16, 2022DEF 14A	DEF 14A	Proxy statement	Mar 16, 2022
Feb 17, 202210-K	10-K	Annual report, FY2021 — revenue $78.74B (−5% y/y), net income $20.88B, EPS $7.81	Jan 2, 2022

12 current reports (8-K) not listed; the year is on EDGAR.

2021 · 21 filings — 9 × 8-K, 5 × PX14A6G, 3 × 10-Q and 3 other forms

Filed	Form	What it is	Period
Oct 29, 202110-Q	10-Q	Quarterly report, Q3 2021 — revenue $23.34B (+11% y/y), net income $3.67B, EPS $1.37	Oct 3, 2021
Jul 29, 202110-Q	10-Q	Quarterly report, Q2 2021 — revenue $23.31B (+27% y/y), net income $6.28B, EPS $2.35	Jul 4, 2021
Apr 30, 202110-Q	10-Q	Quarterly report, Q1 2021 — revenue $22.32B (+8% y/y), net income $6.20B, EPS $2.32	Apr 4, 2021
Apr 14, 2021PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 12, 2021DEFA14A	DEFA14A	Additional proxy materials	—
Mar 29, 2021PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 26, 2021PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 24, 2021PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 22, 2021PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 10, 2021DEFA14A	DEFA14A	Additional proxy materials	—
Mar 10, 2021DEF 14A	DEF 14A	Proxy statement	Mar 10, 2021
Feb 22, 202110-K	10-K	Annual report, FY2020 — revenue $82.58B (+1% y/y), net income $14.71B, EPS $5.51	Jan 3, 2021

9 current reports (8-K) not listed; the year is on EDGAR.

2020 · 22 filings — 12 × 8-K, 3 × 10-Q, 3 × DEFA14A and 4 other forms

Filed	Form	What it is	Period
Oct 23, 202010-Q	10-Q	Quarterly report, Q3 2020 — revenue $21.08B (+2% y/y), net income $3.55B, EPS $1.33	Sep 27, 2020
Jul 24, 202010-Q	10-Q	Quarterly report, Q2 2020 — revenue $18.34B (−11% y/y), net income $3.63B, EPS $1.36	Jun 28, 2020
Apr 29, 202010-Q	10-Q	Quarterly report, Q1 2020 — revenue $20.69B (+3% y/y), net income $5.80B, EPS $2.17	Mar 29, 2020
Mar 31, 2020DEFA14A	DEFA14A	Additional proxy materials	—
Mar 27, 2020DEFA14A	DEFA14A	Additional proxy materials	—
Mar 16, 2020PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 11, 2020DEFA14A	DEFA14A	Additional proxy materials	—
Mar 11, 2020DEF 14A	DEF 14A	Proxy statement	Mar 11, 2020
Mar 2, 2020PRE 14A	PRE 14A	Preliminary proxy statement	Mar 13, 2020
Feb 18, 202010-K	10-K	Annual report, FY2019 — revenue $82.06B (+1% y/y), net income $15.12B, EPS $5.63	Dec 29, 2019

12 current reports (8-K) not listed; the year is on EDGAR.

2019 · 22 filings — 14 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms

Filed	Form	What it is	Period
Oct 28, 201910-Q	10-Q	Quarterly report, Q3 2019 — revenue $20.73B (+2% y/y), net income $1.75B, EPS $0.66	Sep 29, 2019
Jul 29, 201910-Q	10-Q	Quarterly report, Q2 2019 — revenue $20.56B (−1% y/y), net income $5.61B, EPS $2.08	Jun 30, 2019
May 1, 201910-Q	10-Q	Quarterly report, Q1 2019 — revenue $20.02B (+0% y/y), net income $3.75B, EPS $1.39	Mar 31, 2019
Apr 3, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Mar 19, 2019PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Mar 13, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Mar 13, 2019DEF 14A	DEF 14A	Proxy statement	Apr 25, 2019
Feb 20, 201910-K	10-K	Annual report, FY2018 — revenue $81.58B (+7% y/y), net income $15.30B, EPS $5.61	Dec 30, 2018

14 current reports (8-K) not listed; the year is on EDGAR.

2018 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Filed	Form	What it is	Period
Oct 31, 201810-Q	10-Q	Quarterly report, Q3 2018 — revenue $20.35B (+4% y/y), net income $3.93B, EPS $1.44	Sep 30, 2018
Aug 2, 201810-Q	10-Q	Quarterly report, Q2 2018 — revenue $20.83B (+11% y/y), net income $3.95B, EPS $1.45	Jul 1, 2018
May 1, 201810-Q	10-Q	Quarterly report, Q1 2018 — revenue $20.01B (+13% y/y), net income $4.37B, EPS $1.60	Apr 1, 2018
Mar 14, 2018DEFA14A	DEFA14A	Additional proxy materials	—
Mar 14, 2018DEF 14A	DEF 14A	Proxy statement	Apr 26, 2018
Feb 21, 201810-K	10-K	Annual report, FY2017 — revenue $76.45B (+6% y/y), net income $1.30B, EPS $0.47	Dec 31, 2017

11 current reports (8-K) not listed; the year is on EDGAR.

2017 · 19 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 2, 201710-Q	10-Q	Quarterly report, Q3 2017 — revenue $19.65B, net income $3.76B, EPS $1.37	Oct 1, 2017
Aug 3, 201710-Q	10-Q	Quarterly report, Q2 2017 — revenue $18.84B, net income $3.83B, EPS $1.40	Jul 2, 2017
May 8, 201710-Q	10-Q	Quarterly report, Q1 2017 — revenue $17.77B, net income $4.42B, EPS $1.61	Apr 2, 2017
Mar 15, 2017DEFA14A	DEFA14A	Additional proxy materials	—
Mar 15, 2017DEF 14A	DEF 14A	Proxy statement	Jan 1, 2017
Feb 27, 201710-K	10-K	Annual report, FY2016 — revenue $71.89B, net income $16.54B, EPS $5.93	Jan 1, 2017

13 current reports (8-K) not listed; the year is on EDGAR.

2016 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2015 · 21 filings — 13 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms

Counted, not listed; the year is on EDGAR.

2014 · 19 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2013 · 17 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2012 · 27 filings — 19 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms

Counted, not listed; the year is on EDGAR.

2011 · 23 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2010 · 19 filings — 11 × 8-K, 3 × 10-Q, 2 × DFAN14A and 3 other forms

Counted, not listed; the year is on EDGAR.

2009 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2008 · 17 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2007 · 22 filings — 15 × 8-K, 3 × 10-Q, 2 × 8-K/A and 2 other forms

Counted, not listed; the year is on EDGAR.

2006 · 37 filings — 20 × 8-K, 10 × DFAN14A, 3 × 10-Q and 4 other forms

Counted, not listed; the year is on EDGAR.

2005 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2004 · 20 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2003 · 21 filings — 7 × DFAN14A, 6 × 8-K, 3 × 10-Q and 5 other forms

Counted, not listed; the year is on EDGAR.

2002 · 14 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 5 other forms

Counted, not listed; the year is on EDGAR.

2001 · 12 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K405 and 3 other forms

Counted, not listed; the year is on EDGAR.

2000 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × 10-K405/A and 1 other form

Counted, not listed; the year is on EDGAR.

1999 · 7 filings — 3 × 10-Q, 1 × 10-K, 1 × 10-K/A and 2 other forms

Counted, not listed; the year is on EDGAR.

1998 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × 10-K405/A and 1 other form

Counted, not listed; the year is on EDGAR.

1997 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × 10-K405/A and 1 other form

Counted, not listed; the year is on EDGAR.

1996 · 8 filings — 3 × 10-Q, 1 × 10-K/A, 1 × 10-K405 and 3 other forms

Counted, not listed; the year is on EDGAR.

1995 · 6 filings — 3 × 10-Q, 1 × 10-K/A, 1 × 10-K405 and 1 other form

Counted, not listed; the year is on EDGAR.

1994 · 14 filings — 6 × 10-Q, 3 × 10-Q/A, 2 × 8-K and 3 other forms

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 91 filings — 56 × 4, 17 × 144, 4 × SCHEDULE 13G/A and 10 other forms

Filed	Form	What it is	Period
Sep 10, 20264	4	Insider transaction (Form 4)	Sep 8, 2026
Sep 10, 20264	4	Insider transaction (Form 4)	Sep 8, 2026
Sep 10, 20264	4	Insider transaction (Form 4)	Sep 8, 2026
Sep 4, 20264	4	Insider transaction (Form 4)	Sep 2, 2026
Sep 2, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 1, 20263	3	Initial insider holdings (Form 3)	Sep 1, 2026
Aug 18, 20264	4	Insider transaction (Form 4)	Aug 17, 2026
Aug 17, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 14, 20264	4	Insider transaction (Form 4)	Aug 13, 2026
Aug 13, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 11, 2026N-PX	N-PX	Other filings	Jun 30, 2026
Aug 7, 20264	4	Insider transaction (Form 4)	Aug 5, 2026
Aug 7, 20264	4	Insider transaction (Form 4)	Aug 6, 2026
Aug 6, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 6, 202613F-HR	13F-HR	Other filings	Jun 30, 2026
Aug 5, 2026144	144	Notice of proposed sale (Form 144)	—
Jul 21, 20264	4	Insider transaction (Form 4)	Jul 20, 2026
Jul 20, 2026144	144	Notice of proposed sale (Form 144)	—
Jun 25, 202611-K	11-K	Employee plan annual report	Dec 31, 2025
Jun 25, 202611-K	11-K	Employee plan annual report	Dec 31, 2025
Jun 12, 20264	4	Insider transaction (Form 4)	Jun 11, 2026
Jun 11, 20264	4	Insider transaction (Form 4)	Jun 9, 2026
Jun 11, 20264	4	Insider transaction (Form 4)	Jun 9, 2026
Jun 11, 20264	4	Insider transaction (Form 4)	Jun 9, 2026
Jun 11, 2026144	144	Notice of proposed sale (Form 144)	—

The newest 25 of 91 shown; the full year is on EDGAR.

2025 · 101 filings — 70 × 4, 8 × 144, 4 × 13F-HR and 13 other forms

Filed	Form	What it is	Period
Dec 11, 20254	4	Insider transaction (Form 4)	Dec 9, 2025
Dec 11, 20254	4	Insider transaction (Form 4)	Dec 9, 2025
Dec 11, 20254	4	Insider transaction (Form 4)	Dec 9, 2025
Dec 1, 20254	4	Insider transaction (Form 4)	Nov 26, 2025
Dec 1, 20254	4	Insider transaction (Form 4)	Nov 26, 2025
Nov 25, 20254	4	Insider transaction (Form 4)	Nov 21, 2025
Nov 14, 20254	4	Insider transaction (Form 4)	Nov 12, 2025
Nov 13, 202513F-HR	13F-HR	Other filings	Sep 30, 2025
Nov 10, 20254	4	Insider transaction (Form 4)	Nov 6, 2025
Oct 22, 2025SCHEDULE 13G/A	SCHEDULE 13G/A	Other filings	—
Oct 20, 20254	4	Insider transaction (Form 4)	Oct 17, 2025
Oct 17, 2025144	144	Notice of proposed sale (Form 144)	—
Sep 15, 20253	3	Initial insider holdings (Form 3)	Sep 8, 2025
Sep 11, 20254	4	Insider transaction (Form 4)	Sep 9, 2025
Sep 11, 20254	4	Insider transaction (Form 4)	Sep 9, 2025
Sep 11, 20254	4	Insider transaction (Form 4)	Sep 9, 2025
Sep 5, 20254	4	Insider transaction (Form 4)	Sep 4, 2025
Sep 4, 2025144	144	Notice of proposed sale (Form 144)	—
Sep 3, 20254	4	Insider transaction (Form 4)	Aug 29, 2025
Aug 29, 2025144	144	Notice of proposed sale (Form 144)	—
Aug 26, 2025N-PX	N-PX	Other filings	Jun 30, 2025
Aug 25, 20254	4	Insider transaction (Form 4)	Aug 22, 2025
Aug 22, 2025144	144	Notice of proposed sale (Form 144)	—
Aug 18, 20254	4	Insider transaction (Form 4)	Aug 15, 2025
Aug 15, 2025144	144	Notice of proposed sale (Form 144)	—

The newest 25 of 101 shown; the full year is on EDGAR.

2024 · 116 filings — 74 × 4, 9 × SC 13G/A, 6 × 144 and 15 other forms

Filed	Form	What it is	Period
Dec 12, 20244	4	Insider transaction (Form 4)	Dec 12, 2024
Dec 12, 20244	4	Insider transaction (Form 4)	Dec 10, 2024
Dec 12, 20244	4	Insider transaction (Form 4)	Dec 10, 2024
Dec 4, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 13, 202413F-HR	13F-HR	Other filings	Sep 30, 2024
Nov 6, 202425-NSE	25-NSE	Delisting notice from the exchange	—
Nov 1, 2024SC 13G/A	SC 13G/A	Passive holder above 5% (Schedule 13G), amended	—
Oct 31, 20244/A	4/A	Insider transaction (Form 4), amended	May 1, 2024
Oct 21, 20244	4	Insider transaction (Form 4)	May 22, 2024
Oct 18, 2024SC 13G	SC 13G	Passive holder above 5% (Schedule 13G)	—
Oct 18, 2024SC 13G/A	SC 13G/A	Passive holder above 5% (Schedule 13G), amended	—
Oct 15, 20244	4	Insider transaction (Form 4)	Apr 25, 2024
Oct 9, 20243	3	Initial insider holdings (Form 3)	Oct 1, 2024
Sep 12, 20244	4	Insider transaction (Form 4)	Sep 10, 2024
Sep 12, 20244	4	Insider transaction (Form 4)	Sep 10, 2024
Sep 3, 20244	4	Insider transaction (Form 4)	Aug 30, 2024
Aug 30, 2024144	144	Notice of proposed sale (Form 144)	—
Aug 29, 2024N-PX	N-PX	Other filings	Jun 30, 2024
Aug 9, 202413F-HR	13F-HR	Other filings	Jun 30, 2024
Jul 30, 2024SC 13G	SC 13G	Passive holder above 5% (Schedule 13G)	—
Jul 9, 20244	4	Insider transaction (Form 4)	Jul 8, 2024
Jun 25, 202411-K/A	11-K/A	Employee plan annual report, amended	Dec 31, 2023
Jun 24, 202411-K	11-K	Employee plan annual report	Dec 31, 2023
Jun 24, 202411-K	11-K	Employee plan annual report	Dec 31, 2023
Jun 6, 20244	4	Insider transaction (Form 4)	Jun 4, 2024

The newest 25 of 116 shown; the full year is on EDGAR.

2023 · 139 filings — 58 × 425, 54 × 4, 5 × 3 and 9 other forms

Counted, not listed; the year is on EDGAR.

2022 · 103 filings — 79 × 4, 7 × 3, 5 × SC 13G/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2021 · 67 filings — 51 × 4, 3 × 13F-NT, 3 × SC 13G/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2020 · 106 filings — 58 × 4, 20 × S-8 POS, 4 × 13F-NT and 13 other forms

Counted, not listed; the year is on EDGAR.

2019 · 56 filings — 29 × 4, 7 × SC 13G/A, 5 × SC 13G and 9 other forms

Counted, not listed; the year is on EDGAR.

2018 · 67 filings — 50 × 4, 8 × 3, 4 × SC 13G/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2017 · 73 filings — 50 × 4, 5 × FWP, 5 × SC 13G/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2016 · 88 filings — 49 × 4, 8 × FWP, 6 × SC 13G/A and 13 other forms

Counted, not listed; the year is on EDGAR.

2015 · 72 filings — 52 × 4, 9 × SC 13G, 3 × 11-K and 5 other forms

Counted, not listed; the year is on EDGAR.

2014 · 92 filings — 62 × 4, 6 × 3, 5 × FWP and 10 other forms

Counted, not listed; the year is on EDGAR.

2013 · 83 filings — 54 × 4, 6 × FWP, 4 × SC 13G/A and 11 other forms

Counted, not listed; the year is on EDGAR.

2012 · 78 filings — 51 × 4, 6 × NO ACT, 4 × 3 and 8 other forms

Counted, not listed; the year is on EDGAR.

2011 · 140 filings — 75 × 4, 22 × 425, 8 × FWP and 16 other forms

Counted, not listed; the year is on EDGAR.

2010 · 112 filings — 82 × 4, 4 × SC TO-T/A, 3 × 11-K and 13 other forms

Counted, not listed; the year is on EDGAR.

2009 · 140 filings — 110 × 4, 8 × SC TO-T/A, 3 × 11-K and 11 other forms

Counted, not listed; the year is on EDGAR.

2008 · 152 filings — 112 × 4, 9 × SC TO-T/A, 6 × CORRESP and 13 other forms

Counted, not listed; the year is on EDGAR.

2007 · 133 filings — 108 × 4, 4 × 3, 3 × 11-K and 10 other forms

Counted, not listed; the year is on EDGAR.

2006 · 139 filings — 118 × 4, 4 × 11-K, 4 × NO ACT and 9 other forms

Counted, not listed; the year is on EDGAR.

2005 · 145 filings — 104 × 4, 16 × 425, 5 × SC 13G and 10 other forms

Counted, not listed; the year is on EDGAR.

2004 · 147 filings — 121 × 4, 6 × SC 13G/A, 5 × 3 and 7 other forms

Counted, not listed; the year is on EDGAR.

2003 · 137 filings — 118 × 4, 5 × NO ACT, 4 × 3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2002 · 57 filings — 39 × 4, 5 × NO ACT, 5 × SC 13G/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2001 · 33 filings — 7 × 425, 6 × SC 13G, 5 × S-4/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2000 · 14 filings — 6 × 424B3, 4 × SC 13D/A, 1 × S-4 and 3 other forms

Counted, not listed; the year is on EDGAR.

1999 · 7 filings — 2 × S-8 POS, 1 × 424B5, 1 × S-3 and 3 other forms

Counted, not listed; the year is on EDGAR.

1998 · 25 filings — 11 × SC 14D1/A, 4 × SC 13G, 3 × SC 13D and 4 other forms

Counted, not listed; the year is on EDGAR.

1997 · 17 filings — 4 × SC 13D, 3 × S-8, 2 × 3 and 5 other forms

Counted, not listed; the year is on EDGAR.

1996 · 4 filings — 1 × POS AM, 1 × S-4, 1 × SC 13D/A and 1 other form

Counted, not listed; the year is on EDGAR.

1995 · 14 filings — 5 × SC 14D1/A, 2 × S-8 POS, 2 × SC 13D/A and 5 other forms

Counted, not listed; the year is on EDGAR.

1994 · 8 filings — 4 × SC 14D1/A, 1 × 424B2, 1 × 424B5 and 2 other forms

Counted, not listed; the year is on EDGAR.

About this data

Johnson & Johnson (JNJ) has 3,354 filings on EDGAR going back to 1994: 43 annual reports, 107 quarterly reports and 324 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 11, 2026 for the fiscal year ended Dec 28, 2025. The most recent 8-K, on Aug 4, 2026, covered directors or officers; compensation. Over the last 13 months insiders sold $150.7M in 16 sales and bought nothing on the open market; 165 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Johnson & Johnson, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read JNJ's latest 10-K?: JNJ's latest annual report, a 10-K, was filed on Feb 11, 2026 for the fiscal year ended Dec 28, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did JNJ last file an 8-K?: On Aug 4, 2026: directors or officers; compensation. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 15, 2026.
Are JNJ insiders buying or selling?: Over the last 13 months insiders sold $150.7M in 16 sales and bought nothing on the open market; 165 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Schmid Timothy (EVP, WW Chair, MedTech) sold 33,597 shares on Sep 2, 2026 for $9.2M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has JNJ made?: 3,354 filings are on EDGAR under the registrant records that have been Johnson & Johnson, going back to 1994; 1,978 of them are insider ownership forms (Forms 3, 4, 5 and 144).

JNJ SEC filings (2026)

What happened, last 12 months#

September 2026

August 2026

July 2026

June 2026

April 2026

March 2026

February 2026

January 2026

October 2025

Insider transactions#

Reports and proxy statements#

Insider, ownership and other filings#

About this data

FAQ#